Hold. CSL's 72-point Growth Compounder Score reflects steady revenue expansion and profitable scaling in plasma therapies, while a 69-point Value Compounder Score suggests fair intrinsic value at 26× forward earnings. However, Leadership Alignment at 49.3/100 signals material misalignment between insider interests and shareholders—a red flag that tempers conviction despite operational strength.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for CSL FPO [CSL]:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 61/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates CSL FPO [CSL] (CSL.AX) at 61/100 — a Hold — quality is solid but valuation or risk factors cap upside. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Hold. CSL's 72-point Growth Compounder Score reflects steady revenue expansion and profitable scaling in plasma therapies, while a 69-point Value Compounder Score suggests fair intrinsic value at 26× forward earnings. However, Leadershi
CSL.AX's current Stocky Verdict is 61/100, placing it in the "Hold" band. This composite combines a 72/100 Compounder score, 49/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for CSL FPO [CSL] yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
CSL FPO [CSL] scores 49/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Vulnerability Profile for CSL FPO [CSL] covers customer concentration, supply chain risk, refinancing walls, and regulatory exposure. Not yet finalised.
Sign up free and unlock the full analysis on CSL.AX — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for CSL.AX in the app.
